Oxford BioTherapeutics
  • ABOUT
    • COMPANY OVERVIEW
    • SENIOR LEADERSHIP >
      • MANAGEMENT
      • BOARD OF DIRECTORS
      • INVESTORS
    • OFFICES & LABS
  • PIPELINES
  • IO DISCOVERY
    • IMMUNE CHECKPOINT TARGETS
    • IO ANTIBODY ENGINEERING
  • CAREERS
  • NEWS
  • CONTACT

News

Beyond PDL1: OBT has recently discovered a novel T cell modulatory axis, OX001R/L, which is involved in cancer immune escape independent of the PD1/PDL1 axis. "
PRESS RELEASES

​2021

Date
Title
Details
19 Jan 2021
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody® Platform
View here
06 Jan 2021
Kite and Oxford BioTherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours
View here

2020

Date
Title
Details
14 Oct 2020
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
View here
09 Jan 2020
Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors ​
View here

2019

Date
Title
Details
25 Jun 2019
Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate 
View here

2018

Date
Title 
Details
21 Dec 2018
Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated
View here
11 Dec 2018
Oxford BioTherapeutics Expands Strategic Collaboration with  WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
View here
01 Mar 2018
​Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi
View here

2017

Date
Title
Details
12 Sept 2017
Oncology Alliance between Menarini & Oxford BioTherapeutics Progresses Second Candidate MEN1309 into the Clinic, an Antibody Drug Conjugate for the Treatment of Solid Tumors and NHL​​​​
View here
13 Jun 2017
​Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director
View here
09 Feb 2017
Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans​​​​
View here
26 Jan 2017
Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics​​
View here

2016

Date
Title
Details
18 Apr 2016
Boehringer Ingelheim Exercises Option on Second Oncology Target using Oxford BioTherapeutics’ OGAP® System​
View here
04 Apr 2016
Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugates
View here

2015

Date
Title
Details
08 Oct 2015
Oxford BioTherapeutics Appoints Shawn Tomasello to its Board of Directors
View here
30 Jul 2015
Oxford BioTherapeutics Receives $10 Million Capital Term Loan from Silicon Valley Bank​​
View here
23 Feb 2015
Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston​​​
View here
14 Jan 2015
Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to an Oncology Target​​​​​​
View here

2014

Date
Title
Details
25 Nov 2014
$1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukaemia
View here​​
02 Oct 2014
Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance​
View here
07 May 2014
Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse® Antibodies and ImmunoGen Technology to Develop Novel Antibody-Drug Conjugate for HER2-Negative Breast Cancer​
View here

2001 - 2013

Date
Title
Details
09 Dec 2013
Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance
View here
29 Apr 2013
Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
View here
29 Oct 2012
Menarini Group and Oxford BioTherapeutics Collaborate for Development and Manufacture of Novel Antibody-based cancer Drugs
View here
13 Sept 2011
Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer
View here
07 Sept 2011
CMC Biologics Licenses its CHEF1® Expression System to Oxford BioTherapeutics
View here
02 Sept 2011
Oxford BioTherapeutics Licenses Lonza′s GS Gene Expression System™ 
View here
06 Apr 2011
Oxford BioTherapeutics Licenses BioWa′s POTELLIGENT® Technology for the Research and of its Therapeutic Antibodies in Cancer
View here
25 Jan 2011
Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers
View here​
2001-2010
News Archives ​​
View here
MEDIA
Immunotherapies Expose and Exploit Cancer’s Varied Weaknesses
March 18 2021: 
“If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.

Privacy Policy

Legal Notice

Site Map

© 2017 Oxford BioTherapeutics All Rights Reserved
  • ABOUT
    • COMPANY OVERVIEW
    • SENIOR LEADERSHIP >
      • MANAGEMENT
      • BOARD OF DIRECTORS
      • INVESTORS
    • OFFICES & LABS
  • PIPELINES
  • IO DISCOVERY
    • IMMUNE CHECKPOINT TARGETS
    • IO ANTIBODY ENGINEERING
  • CAREERS
  • NEWS
  • CONTACT